223 related articles for article (PubMed ID: 32816202)
21. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.
Subbiah V; Paz-Ares L; Besse B; Moreno V; Peters S; Sala MA; López-Vilariño JA; Fernández C; Kahatt C; Alfaro V; Siguero M; Zeaiter A; Zaman K; López R; Ponce S; Boni V; Arrondeau J; Delord JP; Martínez M; Wannesson L; Antón A; Valdivia J; Awada A; Kristeleit R; Olmedo ME; Rubio MJ; Sarantopoulos J; Chawla SP; Mosquera-Martinez J; D' Arcangelo M; Santoro A; Villalobos VM; Sands J; Trigo J
Lung Cancer; 2020 Dec; 150():90-96. PubMed ID: 33096421
[TBL] [Abstract][Full Text] [Related]
22. A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer.
Cheng Y; Wu C; Wu L; Zhao J; Zhao Y; Chen L; Xin Y; Zhang L; Pan P; Li X; Li J; Dong X; Tang K; Gao E; Yu F
Sci Rep; 2024 Feb; 14(1):3598. PubMed ID: 38351146
[TBL] [Abstract][Full Text] [Related]
23. Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two cases.
Metaxas Y; Cathomas R; Mark M; von Moos R
Lung Cancer; 2016 Dec; 102():136-138. PubMed ID: 27440191
[TBL] [Abstract][Full Text] [Related]
24. A Timeline of Immune Checkpoint Inhibitor Approvals in Small Cell Lung Cancer.
Gill J; Cetnar JP; Prasad V
Trends Cancer; 2020 Sep; 6(9):736-738. PubMed ID: 32616400
[TBL] [Abstract][Full Text] [Related]
25. Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis.
Fudio S; Tabernero J; Subbiah V; Chawla SP; Moreno V; Longo F; Lopez R; Anton A; Trigo JM; Shapiro G; Jeong W; Villalobos VM; Lubomirov R; Fernandez-Teruel C; Alfaro V; Boni V
Cancer Chemother Pharmacol; 2021 Jan; 87(1):113-124. PubMed ID: 33108504
[TBL] [Abstract][Full Text] [Related]
26. Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome.
Benton CB; Chien KS; Tefferi A; Rodriguez J; Ravandi F; Daver N; Jabbour E; Jain N; Alvarado Y; Kwari M; Pierce S; Maiti A; Hornbaker M; Santos MA; Martinez S; Siguero M; Zblewski D; Al-Kali A; Hogan WJ; Kantarjian H; Pardanani A; Garcia-Manero G
Hematol Oncol; 2019 Feb; 37(1):96-102. PubMed ID: 30153704
[TBL] [Abstract][Full Text] [Related]
27. Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer.
Hanvesakul R; Rengarajan B; Naveh N; Boccuti A; Park JE; Adeyemi A; Caisip C; Jansen JP; Wilson FR
J Comp Eff Res; 2023 May; 12(5):e220098. PubMed ID: 37079341
[No Abstract] [Full Text] [Related]
28. Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer.
Fernandez-Teruel C; Gonzalez I; Trocóniz IF; Lubomirov R; Soto A; Fudio S
Clin Pharmacokinet; 2019 Mar; 58(3):363-374. PubMed ID: 30090974
[TBL] [Abstract][Full Text] [Related]
29. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years.
Braun MM; Farag-El-Massah S; Xu K; Coté TR
Nat Rev Drug Discov; 2010 Jul; 9(7):519-22. PubMed ID: 20531273
[TBL] [Abstract][Full Text] [Related]
30. Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine.
van Andel L; Rosing H; Lubomirov R; Avilés P; Fudio S; Tibben MM; Nan-Offeringa L; Schellens JHM; Beijnen JH
J Pharm Biomed Anal; 2018 Sep; 158():160-165. PubMed ID: 29883879
[TBL] [Abstract][Full Text] [Related]
31. Promoters of ASCL1- and NEUROD1-dependent genes are specific targets of lurbinectedin in SCLC cells.
Costanzo F; Martínez Diez M; Santamaría Nuñez G; Díaz-Hernandéz JI; Genes Robles CM; Díez Pérez J; Compe E; Ricci R; Li TK; Coin F; Martínez Leal JF; Garrido-Martin EM; Egly JM
EMBO Mol Med; 2022 Apr; 14(4):e14841. PubMed ID: 35263037
[TBL] [Abstract][Full Text] [Related]
32. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
33. Lurbinectedin (Zepzelca) for small-cell lung cancer.
Med Lett Drugs Ther; 2022 Nov; 64(1663):e198-e199. PubMed ID: 36384771
[No Abstract] [Full Text] [Related]
34. US FDA oncology drug approvals in 2014.
Wolford JE; Tewari KS
Future Oncol; 2015; 11(13):1931-45. PubMed ID: 26039742
[TBL] [Abstract][Full Text] [Related]
35. Comparative Effectiveness of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in the Post-Platinum Setting: A Real-World Canadian Synthetic Control Arm Analysis.
Boyne DJ; Dawe DE; Shakir H; Joe-Uzuegbu O; Farah E; Pabani A; Baratta C; Brenner DR; Cheung WY
Target Oncol; 2023 Sep; 18(5):697-705. PubMed ID: 37656263
[TBL] [Abstract][Full Text] [Related]
36. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
Takahashi R; Mabuchi S; Kawano M; Sasano T; Matsumoto Y; Kuroda H; Kozasa K; Hashimoto K; Sawada K; Kimura T
PLoS One; 2016; 11(3):e0151050. PubMed ID: 26986199
[TBL] [Abstract][Full Text] [Related]
37. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
[TBL] [Abstract][Full Text] [Related]
38. Lurbinectedin-Induced Tumor Lysis Syndrome in Small Cell Neuroendocrine Cancer of the Cecum: A First-Ever Case Report.
Wahab A; Rafae A; Mushtaq K; Venkata K; Sarmad R
Am J Case Rep; 2021 Jun; 22():e932081. PubMed ID: 34125741
[TBL] [Abstract][Full Text] [Related]
39. Incentives for drug development--the curious case of colchicine.
Kesselheim AS; Solomon DH
N Engl J Med; 2010 Jun; 362(22):2045-7. PubMed ID: 20393164
[No Abstract] [Full Text] [Related]
40. Regulators adopt more orphan drugs.
Reardon S
Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
